The original success of Sildenafil undeniably reshaped the pharmaceutical landscape, but placing funds in companies primarily reliant on unbranded versions presents a uncertain picture. Despite early profits were significant, the end of patents and the emergence of discounted alternatives have weakened the customer base. Thus, a thorough analysis o